Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Restorative Care01:19

Restorative Care

Restorative care is provided once a patient has been discharged from a healthcare facility and requires additional services. The additional services include home care, rehabilitation programs, and extended care. Restorative care centers help the patient regain their previous level of functioning or acquire a new level of functioning due to the incapacitating effects of a disease or a disability. It aims to assist patients in enhancing their quality of life by encouraging independence,...
Continuing Care01:25

Continuing Care

Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
Nursing Process for Patient and Caregiver Teaching I: Assessment and Diagnosis01:24

Nursing Process for Patient and Caregiver Teaching I: Assessment and Diagnosis

The nursing process provides a clinical decision-making framework for patients and families to establish and implement a personalized care plan. Since part of the nurse's duties is to teach patients, the steps of the nursing process are the most effective way to approach instruction. The nursing process and the teaching-learning process are inextricably linked.
It is critical to determine the patient's learning needs during the assessment. Determination of learning needs compounds data from the...
Documentation in Long-Term and Home Healthcare Setting01:29

Documentation in Long-Term and Home Healthcare Setting

Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

EClinicalMedicine·2026
Same author

Differential cytokine architecture in patients treated with CART19 versus CART22.

Journal for immunotherapy of cancer·2026
Same author

Advancing the applications of liquid biopsies in oncology.

Nature reviews. Genetics·2026
Same author

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?

Cancers·2026
Same author

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

Nature communications·2026
Same author

Life lost due to the COVID-19 pandemic: A model-based cohort analysis of mortality displacement in the registered population of England.

PloS one·2026

Related Experiment Video

Updated: May 12, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

12.5K

Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation

Kyaw L Aung1, Emma Donald2, Gillian Ellison2

  • 1Clinical and Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, United Kingdom.

The Journal of Molecular Diagnostics : JMD
|March 18, 2014
PubMed
Summary

BRAF mutation testing in circulating free DNA (cfDNA) shows promise for melanoma diagnosis. Optimized criteria enhance sensitivity for detecting BRAF mutations in plasma and serum cfDNA.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.9K

Related Experiment Videos

Last Updated: May 12, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

12.5K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.9K

Area of Science:

  • Molecular Oncology
  • Genetics
  • Biomarker Discovery

Background:

  • Circulating free DNA (cfDNA) analysis offers a non-invasive method for tumor mutation detection.
  • Amplification Refractory Mutation System (ARMS) is a sensitive technique for detecting specific mutations.
  • Validating cfDNA assays and establishing matrix-specific criteria are crucial for clinical utility.

Purpose of the Study:

  • To validate BRAF mutation testing using cfDNA from plasma and serum in advanced melanoma patients.
  • To establish and validate cfDNA-specific mutation calling criteria for improved accuracy.
  • To compare the performance of cfDNA BRAF mutation detection in plasma versus serum.

Main Methods:

  • Analysis of plasma- and serum-derived cfDNA from 221 advanced melanoma patients for BRAF c.1799T>A (p.V600E) mutation using ARMS.
  • Two-stage blinded study design to define and validate cfDNA-specific mutation calling criteria.
  • Comparison of cfDNA concentrations, sensitivity, and specificity between serum and plasma matrices.

Main Results:

  • Optimized cfDNA mutation calling criteria increased BRAF mutation detection sensitivity without compromising specificity.
  • Sensitivity for BRAF mutation detection was 44% in serum and 52% in plasma.
  • Specificity was high (96%) in both serum and plasma, with plasma showing a higher proportion of tumor-derived cfDNA.

Conclusions:

  • Optimized mutation calling criteria enhance the sensitivity of BRAF mutation detection in cfDNA.
  • Plasma cfDNA may be a more suitable matrix for detecting tumor-derived mutations due to a higher mutant DNA proportion.
  • cfDNA BRAF mutation testing holds significant potential as a surrogate for tumor biopsy in melanoma management.